| US 7,598,423 B2 | ||
| Potentiators of glutamate receptors | ||
| Thomas Daniel Aicher, Superior, Colo. (US); Guillermo S. Cortez, Indianapolis, Ind. (US); Todd Michael Groendyke, Ann Arbor, Mich. (US); Albert Khilevich, Westfield, Ind. (US); James Allen Knobelsdorf, Fishers, Ind. (US); Fredrik Pehr Marmsater, Longmont, Colo. (US); Jeffrey Michael Schkeryantz, Fishers, Ind. (US); Tony Pisal Tang, Longmont, Colo. (US); and Nicholas Andrew Magnus, Indianapolis, Ind. (US) | ||
| Assigned to Eli Lilly and Company, Indianapolis, Ind. (US) | ||
| Appl. No. 11/718,753 PCT Filed Nov. 15, 2005, PCT No. PCT/US2005/041441 § 371(c)(1), (2), (4) Date May 07, 2007, PCT Pub. No. WO2006/057870, PCT Pub. Date Jun. 01, 2006. |
||
| Claims priority of provisional application 60/630060, filed on Nov. 22, 2004. | ||
| Prior Publication US 2008/0139505 A1, Jun. 12, 2008 | ||
| Int. Cl. C07D 239/26 (2006.01); C07D 239/28 (2006.01); C07D 241/10 (2006.01); C07D 401/10 (2006.01); C07D 213/02 (2006.01); C07D 291/04 (2006.01); C07D 271/06 (2006.01); C07D 277/20 (2006.01); C07D 417/10 (2006.01); C07D 333/06 (2006.01); C07D 319/06 (2006.01); C07C 49/76 (2006.01) | ||
| U.S. Cl. 568—331 [549/75; 549/78; 549/274; 549/495; 549/502; 548/122; 548/132; 548/182; 548/194; 548/206; 548/236; 548/243; 548/247; 548/253; 548/263.2; 548/316.4; 548/544; 546/268.1; 546/340; 544/297; 544/298; 544/335; 544/336] | 23 Claims |
1. A compound of formula I
 R1 is selected from the group consisting of C1-C5 alkyl, C3-C7 cycloalkyl, C4-C8 cycloalkylalkyl, phenyl and substituted phenyl;
R2 is selected from the group consisting of hydrogen, C1-C5 alkyl, substituted C1-C5 alkyl, halo, phenyl, substituted phenyl,
C1-C3 fluoroalkyl, CN, CO2R3, thiophenyl, substituted thiophenyl, thiazolyl, substituted thiazoyl, furanyl, substituted furanyl, pyridinyl, substituted
pyridinyl, oxazolyl, substituted oxazloyl, isothiazolyl, substituted isothiazoyl, isoxazolyl, substituted isoxazolyl, 1,2,4-oxadiazolyl,
substituted 1,2,4-oxadiazolyl, pyrimidinyl, substituted pyrimidinyl, pyridazinyl, and substituted pyridazinyl;
X is selected from the group consisting of O, S(O)m, and NR3;
Y is selected from the group consisting of C1-C3 alkanediyl and substituted C1-C3 alkanediyl;
Ar1 and Ar2 are independently selected from the group consisting of phenylene and substituted phenylene;
L is selected from the group consisting of C1-C5 alkanediyl, substituted C1-C5 alkanediyl, and —G—C(═W)—J—;
W is CR3R3, O or NR3;
G and J are independently selected from the group consisting of a bond and C1-C3 alkanediyl;
R3 is independently hydrogen or C1-C5 alkyl;
Z is selected from the group consisting of (CH2)nCOOH,
 m is 0, 1, or 2;
n and q are independently 0, 1, 2 or 3; and pharmaceutically acceptable salts thereof.
|